Management of Acquired Factor VIII Inhibitors With NovoSeven and Obizur.
Cureus
; 13(10): e19145, 2021 Oct.
Article
in English
| MEDLINE | ID: covidwho-1513126
ABSTRACT
Acquired hemophilia A (AHA) is a rare hemorrhagic disorder caused by the production of autoantibodies against coagulation factor VIII (FVIII). AHA is associated with significant morbidity and mortality primarily as a result of bleeding. Although many disorders are associated with the development of these inhibitors, up to 50% of cases remain idiopathic. The approach to therapy involves an initial strategy often to control acute bleeding episodes followed by definitive treatment to eradicate the inhibitor with immunosuppressive agents. We present the case of a 63-year-old Caucasian male hospitalized for severe Covid-19 who developed bleeding due to an acquired FVIII inhibitor that had never been treated definitively. Our case presentation focuses on in-hospital management of this patient's acute bleeding episodes with by-passing agents and recombinant porcine factor VIII.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Type of study:
Case report
/
Observational study
Language:
English
Journal:
Cureus
Year:
2021
Document Type:
Article
Affiliation country:
Cureus.19145
Similar
MEDLINE
...
LILACS
LIS